News

BioVaxys Prepares for Groundbreaking Study on reduced ACE2 binding capabilities of Hapten-modified SARS-CoV-2 proteins

– Potential for superior tolerability to mRNA and Adenovirus Vector vaccines – Production Agreement signed with Millipore-Sigma for SARS-CoV-2 Vaccine Supply VANCOUVER, BC, Sept. 23, 2021 — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “Company”), announced today that it has initiated what could be a scientifically groundbreaking study on the reduced ACE2 binding […]

BioVaxys Engages Life Sciences Public Relations and Market Communications Firm 6 Degrees

VANCOUVER, British Columbia, Sept. 20, 2021 — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys”) announced today that it has engaged life sciences and healthcare communications firm 6 Degrees to handle its strategic communications planning, public and media relations, and social media presence. Located in the US biopharmaceutical hub of New York/New Jersey/Pennsylvania, […]

BioVaxys Cancer Vaccine Manufacturing Partner Bio Elpida Reaches Bioproduction Milestone

VANCOUVER, British Columbia, Sept. 17, 2021 — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys”), announced today that cancer vaccine manufacturing partner Bio Elpida in Lyon, France, has reached major milestones in the development of the bioproduction process for BVX-0918A, BioVaxys’ ovarian cancer vaccine and is beginning the next phase of manufacturing process development. […]

BioVaxys Bioproduction Partner WuXi Biologics Completes Synthesis Of Recombinant SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH Programs

VANCOUVER, BC, Sept. 14, 2021 — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys”), announced today that global CDMO partner WuXi Biologics, has completed the synthesis of recombinant SARS-CoV-2 s-protein for BVX-0320, the company’s COVID-19 vaccine candidate, and CoviDTH, its immunodiagnostic product.  Both are headed for clinical trials, with BioVaxys having begun preparing an […]

Further Study in humans shows that the DTH response, the basis for CoviDTH, is highly durable and persists for at least one year after COVID-19 exposure or vaccine administration

VANCOUVER, BC and SAN CRISTÓBAL DE LA LAGUNA, Spain, Sept. 7, 2021 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “the Company”) is pleased to announce that the Scientific Advisor for its CoviDTH program, Yvelise Barrios, MD, PhD, and Clinical Immunologist at Hospital Universitario de Canarias, Tenerife, Spain, has been invited to […]

Clinical Trial Affirms CoviDTH Diagnostic Approach To Screen For T Cell-mediated Immune Response To SARS-CoV-2 Is Safe And Effective In Humans

YVELISE BARRIOS, MD, PhD, IMMUNOLOGIST AND LEADING EXPERT IN THE CLINICAL USE OF DELAYED TYPE HYPERSENSITIVITY (“DTH”), THE MECHANISM BEHIND CoviDTH, JOINS BIOVAXYS AS SCIENTIFIC ADVISER Vancouver, British Columbia and San Cristóbal de  La Laguna, Tenerife, Spain, August 3rd,  2021,   BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTCQB:BVAXF) (“BioVaxys” or “the Company”) is pleased to announce that […]

Biovaxys Closes Final Tranche of Non-brokered Private Placement

Vancouver, British Columbia, July 28th, 2021 BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTCQB:BVAXF) (“BioVaxys” or the “Company”) is pleased to announce that it has closed the second and final tranche of its previously announced non-brokered private placement (the “Private Placement“). Under the final tranche (the “Final Tranche“) of the Private Placement, the Company issued 5,349,455 […]

FDA Provides Necessary Guidance For Biovaxys To Begin Preparation Of IND For Phase I/Ii Clinical Trials Of CoviDTH

Vancouver, British Columbia, July 22nd, 2021 BioVaxys Technology Corp. (CSE: BIOV; FRA:5LB; OTCQB: BVAXF) (“BioVaxys”), is pleased to announce today that the US Food and Drug Administration (“FDA”) has provided its official Written Response to the Company’s request for a Pre-IND Type B review of CoviDTH as a diagnostic for evaluating T-cell immune response to […]

BioVaxys Announces Non-Brokered Private Placement

Vancouver, British Columbia, June 28th, 2021 BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTCQB:BVAXF) (“BioVaxys” or the “Company”) is pleased to announce a non-brokered private placement (the “Private Placement”) consisting of up to 9,090,909 units (“Units”) at a price of $0.22 per Unit for total gross proceeds of up to approximately $2,000,000. Each Unit consists of […]

Biovaxys Receives Positive FDA Response For Pre-Ind Review For CoviDTH Clinical Development

Vancouver, British Columbia, June 14th, 2021 BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTCQB:BVAXF) (“BioVaxys”), is pleased to announce today that the US Food and Drug Administration (FDA) has reviewed its Pre-IND request for a Type B review of its CoviDTH program and has determined that a Written Response is sufficient to address the Company’s questions […]